PCM
BPMC

Prelude Capital Management’s Blueprint Medicines BPMC Stock Holding History

Prelude Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-60,154
Closed -$7.71M – 1157
2025
Q2 		$7.71M Buy
+60,154
New +$6.25M 0.75% 16
2025
Q1 		– Sell
-8,552
Closed -$746K – 1212
2024
Q4 		$746K Sell
8,552
-1,668
-16% -$153K 0.05% 460
2024
Q3 		$945K Buy
+10,220
New +$1.02M 0.06% 397
2022
Q1 		– Sell
-8,950
Closed -$959K – 1849
2021
Q4 		$959K Sell
8,950
-1
-0% -$105 0.02% 641
2021
Q3 		$920K Buy
8,951
+1,001
+13% +$93.2K 0.02% 603
2021
Q2 		$699K Buy
+7,950
New +$728K 0.02% 786
2020
Q4 		– Sell
-950
Closed -$88K – 1334
2020
Q3 		$88K Buy
+950
New +$73.2K ﹤0.01% 952
2020
Q1 		– Sell
-7,500
Closed -$601K – 1469
2019
Q4 		$601K Buy
+7,500
New +$561K 0.02% 518
2018
Q4 		– Sell
-9,172
Closed -$716K – 1789
2018
Q3 		$716K Buy
9,172
+5,593
+156% +$389K 0.04% 438
2018
Q2 		$227K Buy
+3,579
New +$285K 0.01% 723
2017
Q3 		– Sell
-235
Closed -$12K – 1629
2017
Q2 		$12K Buy
+235
New +$9.98K ﹤0.01% 1359

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prelude Capital Management's BPMC Position: Q3 2025 in Review

Prelude Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 60,154 shares — an estimated $7.71M sold.

Prelude Capital Management first reported a position in BPMC in Q2 2017 and held it in 11 quarters. The position peaked at $7.71M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Prelude Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 60,154 Blueprint Medicines shares in Q3 2025, an estimated $7.71M.
  • Prelude Capital Management first reported a position in Blueprint Medicines in Q2 2017 and held it in 11 quarters.
  • Prelude Capital Management's Blueprint Medicines position peaked at $7.71M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.